PHI releases App Suite 2 – more apps and greater applicability

PHI will launch the HoloMonitor App Suite™ 2 software together with an integrated e-commerce website on April 29, 2019.

App Suite 2 is the second release in a series of planned App Suite releases, developed to provide automated live-cell studies to researchers worldwide in an unprecedented user-friendly workflow, using PHI’s HoloMonitor-technology. The modular software facilitates a more dynamic business model and positions the company for increased growth through strategic partnerships.

App Suite automatically performs live-cell population analysis by quantifying individual cells over time. The software automatically records and processes multiple time-lapse movies, while presenting the data analysis results in real time. As all assays are label-free for uncompromised physiological relevance, recorded experi­mental data may be reused with other App Suite assays to obtain multiple measurements from a cell culture sample.

The new website offers a user-friendly design with improved navigation and functionality, allowing customers to concisely overview the full product portfolio. The webshop (e-commerce) together with App Suite provides increased flexibility for PHI customers, as they can order and choose applications for their specific needs.

For additional information regarding App Suite 2, visit or now also on April 29.

For additional information, please contact:
Carolina Silvandersson


About Us

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first HoloMonitor instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.




Documents & Links